Emerging data suggest this peptide, a dual stimulator targeting both incretin and another hormone, could offer a promising advancement for body treatment. Initial clinical trials have shown substantial losses in visceral mass , possibly surpassing other body composition therapies . However , more study is necessary to fully understand its long-term